Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.15 Billion INR | -250.47% |
| 2022 | 769.42 Million INR | -12.04% |
| 2021 | 874.75 Million INR | -19.94% |
| 2020 | 1.09 Billion INR | -1.6% |
| 2019 | 1.11 Billion INR | 27.77% |
| 2018 | 869 Million INR | 7.28% |
| 2017 | 810.04 Million INR | -54.57% |
| 2016 | 1.78 Billion INR | 2.54% |
| 2015 | 1.73 Billion INR | 185.03% |
| 2014 | 610.1 Million INR | -5.06% |
| 2013 | 642.65 Million INR | -25.36% |
| 2012 | 861.05 Million INR | 695.0% |
| 2011 | -144.71 Million INR | -48.52% |
| 2010 | -97.43 Million INR | -26.87% |
| 2009 | -76.8 Million INR | -73.2% |
| 2008 | -44.34 Million INR | -76.92% |
| 2007 | -25.06 Million INR | -171.47% |
| 2006 | 35.07 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.4 Billion INR | 221.24% |
| 2024 Q2 | 501.78 Million INR | -56.5% |
| 2023 Q2 | 573.73 Million INR | -16.07% |
| 2023 Q1 | 683.58 Million INR | -11.16% |
| 2023 Q4 | -1.15 Billion INR | -171.06% |
| 2023 Q3 | 1.62 Billion INR | 183.99% |
| 2023 FY | -1.15 Billion INR | -250.47% |
| 2022 Q2 | 621.6 Million INR | -53.94% |
| 2022 Q4 | 769.42 Million INR | -47.08% |
| 2022 FY | 769.42 Million INR | -12.04% |
| 2022 Q1 | 1.34 Billion INR | 54.26% |
| 2022 Q3 | 1.45 Billion INR | 133.89% |
| 2021 Q2 | 797.58 Million INR | -50.36% |
| 2021 FY | 874.75 Million INR | -19.94% |
| 2021 Q1 | 1.6 Billion INR | 47.05% |
| 2021 Q4 | 874.75 Million INR | -33.85% |
| 2021 Q3 | 1.32 Billion INR | 65.8% |
| 2020 Q3 | 1.32 Billion INR | 14.87% |
| 2020 FY | 1.09 Billion INR | -1.6% |
| 2020 Q1 | 1.03 Billion INR | -6.95% |
| 2020 Q4 | 1.09 Billion INR | -17.55% |
| 2020 Q2 | 1.15 Billion INR | 11.67% |
| 2019 Q2 | 848.68 Million INR | -20.41% |
| 2019 Q1 | 1.06 Billion INR | 22.7% |
| 2019 FY | 1.11 Billion INR | 27.77% |
| 2019 Q3 | 1.08 Billion INR | 27.71% |
| 2019 Q4 | 1.11 Billion INR | 2.44% |
| 2018 Q2 | 412.34 Million INR | -24.21% |
| 2018 FY | 869 Million INR | 7.28% |
| 2018 Q4 | 869 Million INR | -17.67% |
| 2018 Q3 | 1.05 Billion INR | 155.96% |
| 2018 Q1 | 544.1 Million INR | 139.53% |
| 2017 FY | 810.04 Million INR | -54.57% |
| 2017 Q3 | 2.05 Billion INR | 103.11% |
| 2017 Q2 | 1.01 Billion INR | -32.67% |
| 2017 Q1 | 1.5 Billion INR | 311.85% |
| 2017 Q4 | 227.15 Million INR | -88.96% |
| 2016 Q4 | 365.45 Million INR | -67.28% |
| 2016 FY | 1.78 Billion INR | 2.54% |
| 2016 Q1 | 781.76 Million INR | -55.05% |
| 2016 Q2 | -354.51 Million INR | -145.35% |
| 2016 Q3 | 1.11 Billion INR | 415.01% |
| 2015 Q4 | 1.73 Billion INR | 0.0% |
| 2015 FY | 1.73 Billion INR | 185.03% |
| 2014 FY | 610.1 Million INR | -5.06% |
| 2013 FY | 642.65 Million INR | -25.36% |
| 2012 FY | 861.05 Million INR | 695.0% |
| 2012 Q2 | -36.41 Million INR | 0.0% |
| 2012 Q4 | 861.05 Million INR | 0.0% |
| 2011 FY | -144.71 Million INR | -48.52% |
| 2010 FY | -97.43 Million INR | -26.87% |
| 2009 FY | -76.8 Million INR | -73.2% |
| 2008 FY | -44.34 Million INR | -76.92% |
| 2007 FY | -25.06 Million INR | -171.47% |
| 2006 FY | 35.07 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 129.948% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 131.347% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 59.272% |
| Granules India Limited | 9.28 Billion INR | 112.467% |
| Indoco Remedies Limited | 6.47 Billion INR | 117.877% |
| Achyut Healthcare Limited | -3.74 Million INR | -30806.353% |
| Ajanta Pharma Limited | -954.9 Million INR | -21.243% |
| Alkem Laboratories Limited | -1.6 Billion INR | 28.063% |
| Alpa Laboratories Limited | 35.36 Million INR | 3373.908% |
| Brooks Laboratories Limited | 49.48 Million INR | 2439.602% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 76.902% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 135.095% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 108.966% |
| Eris Lifesciences Limited | 13.8 Billion INR | 108.386% |
| FDC Limited | -57.75 Million INR | -1904.696% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 72.983% |
| Gufic Biosciences Limited | 3.19 Billion INR | 136.244% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 72.123% |
| Ipca Laboratories Limited | 11.41 Billion INR | 110.142% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 16.704% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 159.896% |
| Lasa Supergenerics Limited | 205.79 Million INR | 662.564% |
| Laurus Labs Limited | 24.38 Billion INR | 104.748% |
| Lupin Limited | 17.19 Billion INR | 106.734% |
| Mankind Pharma Limited | -9.9 Billion INR | 88.315% |
| Medicamen Biotech Limited | 160.31 Million INR | 822.169% |
| Medico Remedies Limited | 78.67 Million INR | 1571.525% |
| Megasoft Limited | 1.28 Billion INR | 190.059% |
| NATCO Pharma Limited | -5.81 Billion INR | 80.097% |
| Piramal Pharma Limited | 42.27 Billion INR | 102.739% |
| RPG Life Sciences Limited | -364.7 Million INR | -217.453% |
| Sigachi Industries Limited | 859.94 Million INR | 234.63% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.402% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 898.582% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 2605.36% |
| Unichem Laboratories Limited | 931.91 Million INR | 224.234% |
| Wanbury Limited | 1.1 Billion INR | 204.691% |
| Windlas Biotech Limited | -273.04 Million INR | -324.023% |
| ZIM Laboratories Limited | 983.6 Million INR | 217.705% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 129.595% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -22.93% |
| Divi's Laboratories Limited | -39.77 Billion INR | 97.089% |
| Hester Biosciences Limited | 2.29 Billion INR | 150.541% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 50.692% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -365.349% |
| Bal Pharma Limited | 1.26 Billion INR | 191.626% |
| Strides Pharma Science Limited | 23.25 Billion INR | 104.978% |
| Venus Remedies Limited | -267.7 Million INR | -332.481% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 144.326% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 118.803% |
| Shilpa Medicare Limited | 9.06 Billion INR | 112.765% |
| Aarti Drugs Limited | 5.54 Billion INR | 120.866% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -5.126% |
| Suven Life Sciences Limited | -1.63 Billion INR | 29.09% |
| Ind-Swift Limited | 9.5 Billion INR | 112.176% |
| Valiant Laboratories Limited | -295.03 Million INR | -292.416% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 141.038% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 111.544% |
| Themis Medicare Limited | 764.96 Million INR | 251.348% |
| Hikal Limited | 7.96 Billion INR | 114.532% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 103.637% |
| Sequent Scientific Limited | 4.17 Billion INR | 127.706% |
| Novartis India Limited | -5.89 Billion INR | 80.347% |
| Wockhardt Limited | 18.27 Billion INR | 106.337% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 104.277% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -6176.439% |
| Neuland Laboratories Limited | -214.05 Million INR | -440.859% |
| Morepen Laboratories Limited | -231.17 Million INR | -400.814% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1064.48% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 218.645% |